16 OC Deficiency of iron, folic acid and vitamin B12 in inflammatory bowel disease

2002 ◽  
Vol 34 ◽  
pp. A80
Author(s):  
D. Guagnozzi ◽  
A. Aratari ◽  
V. D'Ovidio ◽  
A. Viscido ◽  
P.L. Ialongo ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Folic Acid ◽  
Vitamin B12 ◽  
Bowel Disease ◽  
Inflammatory Bowel ◽  
Iron Folic Acid

scholarly journals Serum transferrin receptor-ferritin index as a marker of iron deficiency anemia in active inflammatory bowel disease patients in Indian population

2021 ◽  
Vol 9 (9) ◽  
pp. 2796
Author(s):  
Deepika Gujjarlapaudi ◽  
Namburu Veeraiah ◽  
Syed Hassan Naveed ◽  
Duvvuru Nageswara Reddy
Keyword(s):  
Inflammatory Bowel Disease ◽  
Folic Acid ◽  
Iron Deficiency ◽  
Vitamin B12 ◽  
Bowel Disease ◽  
Transferrin Receptor ◽  
Group I ◽  
Group A ◽  
Inflammatory Bowel ◽  
Group Ii

Background: Anemia is most common complication in IBD (inflammatory bowel disease). The aim of the study was to assess the sTfR-F (soluble transferrin receptor-ferritin) index as early marker of IDA (iron deficiency anaemia) in IBD.Methods: Retrospective cross sectional study has 480 cases of IBD (group I ) with controls 220 (group II), CBP, serum hsCRP, serum iron, TIBC (total iron binding capacity), sTfR, ferritin, fecal calprotectin, vitamin B12, folic acid were assessed.Results: In study I, group I was compared with group II showed (66.5%) patients had active disease and in that 65.0% of UC, 32.1% of CD and 2.9% others colitis had anemia. In study II, subgroup I 56.4% had IDA subgroup II 7.3% had ferritin between 30-100 ng/ml combi subgroup III 23.3% had ferritin>100 ng/ml (ACD, anaemia of chronic disease) subgroup IV 5.6% had vitamin B12 and folic acid deficiency excluding sTfR-F analysis. In study III, subdivided to identify IDA with sTfR-F index as group A 60.8% had sTfR-F index>2, group B 32.6% had sTfR-F index=1-2 and group C 3 (6.2%) had sTfR-F index<1. Intially diagnosed IDA was 56.4%, in addition with group A, IDA has increased by 66.5%. In study IV, in IDA, sensitivity of sTfR-F index was100%, sTfR 89% and SF 85%. Specificity of sTfR and sTfR-F index were 80.60% and SF has low specificity 73.90%. In study V, a statistical significance was seen more in female than male and in children than in adults with sTfR-F index in IDA.Conclusions: sTfR-F index as an early diagnostic marker, in differentiating IDA, ACD and combi in IBD patients.

Vitamin B12 Deficiency in Inflammatory Bowel Disease

2014 ◽  
pp. 1 ◽  
Author(s):  
Robert Battat ◽  
Uri Kopylov ◽  
Andrew Szilagyi ◽  
Anjali Saxena ◽  
David S. Rosenblatt ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Vitamin B12 ◽  
Bowel Disease ◽  
Vitamin B12 Deficiency ◽  
B12 Deficiency ◽  
Inflammatory Bowel

scholarly journals Effect of a Nutrition Support Formula in Adults With Inflammatory Bowel Disease: A Pilot Study

2019 ◽  
Vol 8 ◽  
pp. 216495611986725
Author(s):  
Jennifer J Ryan ◽  
Douglas A Hanes ◽  
Ryan D Bradley ◽  
Nikhat Contractor
Keyword(s):  
Inflammatory Bowel Disease ◽  
Pilot Study ◽  
Blood Cell ◽  
Vitamin B12 ◽  
Bowel Disease ◽  
Inflammatory Markers ◽  
Nutrition Support ◽  
Serum Folate ◽  
Inflammatory Bowel ◽  
Rbc Count

Background Due to the high prevalence of nutrient deficiencies in patients with inflammatory bowel disease (IBD), routine monitoring of nutrient status and supplementation are recommended. Objective This preliminary study was implemented to prospectively identify potential effects of a nutrition support formula on blood nutrient parameters in adults with IBD. Methods Ten adults with Crohn’s disease or ulcerative colitis were recruited from the Portland, Oregon, metropolitan area into a single-arm, open-label pilot study. Participants consumed a nutrition support beverage twice daily for 12 weeks. The formula contained a mixture of micronutrients (including methylated forms of folate and vitamin B12), macronutrients, and phytonutrients (including curcumin, xanthohumol, ginger compounds, and quercetin). Primary measures were the following parameters: folate, vitamin B12, red blood cell (RBC) count, hemoglobin, hematocrit, electrolytes, and albumin. Exploratory measures included a food frequency questionnaire, circulating blood cell counts, and inflammatory markers. Results Nine participants completed the study and one withdrew. Adherence was 98%. Serum folate increased 48.7% ( P = .029), serum vitamin B12 increased 17.4% but did not reach statistical significance ( P = .053), and red cell distribution width (RDW) decreased 9.2% ( P = .012) over the 12-week study period. There were minimal shifts in total white blood cell (WBC) counts (−1.0%, P = .845), but percent neutrophils decreased 10.4% ( P = .042) and absolute lymphocyte count increased 18.6% ( P = .048). RBC count, hemoglobin, hematocrit, electrolytes, albumin, and inflammatory markers did not change significantly. Post hoc analysis demonstrated that neutrophil–lymphocyte ratio (NLR) decreased 18.4% (not significant, P = .061). Conclusion Serum folate and RDW improved in adults with IBD after 12 weeks. Modulation of leukocyte subtypes was also observed, including a decrease in neutrophils and an increase in lymphocytes, with no change in total WBC count. A randomized, controlled study to further examine effects of the nutrition support formula will be initiated to follow up on this promising, but preliminary investigation.

Vitamin B12 deficiency in inflammatory bowel disease

2017 ◽  
Vol 29 (12) ◽  
pp. 1361-1367 ◽  
Author(s):  
Robert Battat ◽  
Uri Kopylov ◽  
Joshua Byer ◽  
Maida J. Sewitch ◽  
Elham Rahme ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Vitamin B12 ◽  
Bowel Disease ◽  
Vitamin B12 Deficiency ◽  
B12 Deficiency ◽  
Inflammatory Bowel

scholarly journals Evaluation of clinical efficacy of preventive therapy in pregnant women with ulcerative colitis

2021 ◽  
Vol 25 (2) ◽  
pp. 271-276
Author(s):  
O. V. Bulavenko ◽  
I. V. Oleksiienko ◽  
I. V. Prolygina ◽  
S. A. Tarasiuk ◽  
S. V. Balabueva
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Vitamin D ◽  
Folic Acid ◽  
Bowel Disease ◽  
Preventive Therapy ◽  
Chronic Inflammatory Bowel Disease ◽  
Clinical Group ◽  
Inflammatory Bowel ◽  
Chronic Inflammatory Bowel

Annotation. “Voluntary childlessness” as a consequence of fear of infertility, doubts about the ability to cope with pregnancy in the presence of the disease, the hereditary nature of the disease and adverse effects on the fetus; improper medication; self-modification or discontinuation of therapy in patients with CIBD (chronic inflammatory bowel disease) are significant not only medical but also social problems that currently remain unresolved. The aim of this work is to provide up-to-date evidence for the optimal diagnosis and treatment of chronic inflammatory bowel disease before conception, during pregnancy and in the postpartum period. A detailed analysis of the social, somatic, gynecological and obstetric history of women with inflammatory bowel disease was performed. The examined patients were divided into the main group (ulcerative colitis) (n=40) and control groups (almost healthy women) (n=30). The first main clinical group underwent prophylactic therapy using a drug containing active folate of the 4th generation "Quatrefolic" (equivalent to 400 μg of folic acid), potassium iodide 1 table. per day and vitamin D 1000 IU per day, starting from the planning stage of pregnancy). The second major clinical group received, in addition to Quatrefolic and potassium iodide, vitamin D 4,000 IU per day during the pre-pregnancy phase and 2,000 IU per day during pregnancy and 1,000 IU per day in cases of placental dysfunction and anemia. The formation of observation groups was carried out by methods of continuous and selective analysis. Statistical processing of research results was performed using the software package Statistica 6.0. The obtained indicators were processed statistically with the determination of the arithmetic mean (M) and the error of the standard deviation (±m), at p<0,05. Risk ratio (RR) and confidence interval (CI) were determined with a given reliable probability p=95%. Comparison of groups by case frequency was performed using the exact Fisher test (two-way criterion). Pregnant women with ulcerative colitis have a better clinical efficacy of preventive therapy using the 4th generation active folate “Quatrefolic” (equivalent to 400 mcg of folic acid) and vitamin D 4000 IU at the pre-pregnancy stage and 2000 IU after pregnancy verification compared with active folate 4th generation “Quatrefolic” (equivalent to 400 mcg of folic acid) and vitamin D 1000 IU.

Sign in / Sign up

Export Citation Format

Share Document